Company profile
RELAY THERAPEUTICS, INC.
NASDAQ:RLAYBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZOVEGALISIB | phase3 | — | 3 | active |
| ATIRMOCICLIB | phase1 | — | 12 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07584226 | phase1 | recruiting | 2026-03-09 | 2027-12-30 | Relay Therapeutics, Inc. | A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors |
| NCT06789913 | phase2 | recruiting | 2025-06-13 | 2031-07-01 | Relay Therapeutics, Inc. | A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) |
| NCT05216432 | phase1 | recruiting | 2021-12-08 | 2027-04-30 | Relay Therapeutics, Inc. | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer |
| NCT05759949 | phase1 | completed | 2023-03-29 | 2025-03-18 | Relay Therapeutics, Inc. | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors |
| NCT06982521 | phase3 | recruiting | 2025-08-26 | 2028-04-30 | Relay Therapeutics, Inc. | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer |
FDA applications (0)
No records yet.